- Home
- MGNX vs DTI Comparison
MGNX vs DTI Comparison
Compare MGNX & DTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- DTI
- Stock Information
- Founded
- MGNX 2000
- DTI 1984
- Country
- MGNX United States
- DTI United States
- Employees
- MGNX N/A
- DTI N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- DTI Metal Fabrications
- Sector
- MGNX Health Care
- DTI Industrials
- Exchange
- MGNX Nasdaq
- DTI Nasdaq
- Market Cap
- MGNX 70.3M
- DTI 68.0M
- IPO Year
- MGNX 2013
- DTI N/A
- Fundamental
- Price
- MGNX $1.43
- DTI $2.37
- Analyst Decision
- MGNX Hold
- DTI Strong Buy
- Analyst Count
- MGNX 10
- DTI 1
- Target Price
- MGNX $6.83
- DTI $5.50
- AVG Volume (30 Days)
- MGNX 599.1K
- DTI 58.3K
- Earning Date
- MGNX 05-20-2025
- DTI 05-13-2025
- Dividend Yield
- MGNX N/A
- DTI N/A
- EPS Growth
- MGNX N/A
- DTI N/A
- EPS
- MGNX N/A
- DTI 0.09
- Revenue
- MGNX $149,962,000.00
- DTI $154,446,000.00
- Revenue This Year
- MGNX N/A
- DTI $12.21
- Revenue Next Year
- MGNX $80.86
- DTI $6.26
- P/E Ratio
- MGNX N/A
- DTI $26.44
- Revenue Growth
- MGNX 155.26
- DTI 1.59
- 52 Week Low
- MGNX $0.99
- DTI $1.43
- 52 Week High
- MGNX $14.91
- DTI $6.36
- Technical
- Relative Strength Index (RSI)
- MGNX 43.37
- DTI 59.79
- Support Level
- MGNX $1.54
- DTI $2.10
- Resistance Level
- MGNX $1.82
- DTI $2.28
- Average True Range (ATR)
- MGNX 0.15
- DTI 0.13
- MACD
- MGNX 0.01
- DTI 0.07
- Stochastic Oscillator
- MGNX 19.79
- DTI 92.41
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About DTI Drilling Tools International Corporation
Drilling Tools International Corp manufactures, rents, inspects, and refurbishes downhole drilling tools primarily to companies in the oil and natural gas industry for bottom hole assemblies used in onshore and offshore horizontal and directional drilling. The company's United States operations have locations in Texas, California, Louisiana, Oklahoma, Pennsylvania, North Dakota, New Mexico, Utah, and Wyoming. The company's single segment derives revenues from customers by providing oilfield equipment and services to operators in the oil and natural gas sectors.